Mutations in the early growth response 2 (EGR2) gene are associated with some forms of CharcotMarie-Tooth disease (CMT) and other demyelinating neuropathies. These mutations modify the EGR2 binding to specific DNA sequences suggesting a role in the transcriptional control of myelinationspecific genes. Here we show that the D355V mutation, associated with a CMT case combining axonal and demyelinating abnormalities, reduces three times the affinity of EGR2 to its consensus sequence and ten times its affinity to a sequence in the human Cx32 promoter. These findings could indicate that this EGR2 mutation leads to the development of CMT1 through the transcriptional deregulation of Cx32 gene.
INTRODUCTION
Charcot-Marie-Tooth (CMT) neuropathy is frequently associated to either a 1.5 Mb tandem repeat duplication in 17p11.2, including the peripheral myelin protein 22 (PMP22) gene (CMT1A) (Lupsky et al., 1991; Raeymaekers et al., 1991) , or to mutations of PMP22, protein zero (PO), and connexin 32 (Cx32) genes (reviewed in Nelis et al., 1999) . Lately, a whole spectrum of related clinical disorders, ranging from CMT1 to congenital hypomyelination, was found to be associated with mutations in the early growth response 2 (EGR2) gene (Warner et al., 1998; Timmerman et al., 1999; Bellone et al., 1999; Pareyson et al., 2000) .
Egr2, the mouse homologous of EGR2, also known as Krox-20, is a zinc finger transcription factor involved in the control of peripheral myelination. Egr2 knockout mice display a block of Schwann cells (SCs) differentiation with reduced expression of major components of compact myelin such as PO, PMP22, and myelin basic protein (Topilko et al., 1994; Zorick et al., 1999) , thus suggesting the Egr2 requirement for the transactivation of myelination-specific genes. However, evidence for a direct activation of genes specific of pheripheral nervous system (PNS) has not been yet provided.
We have previously described a novel EGR2 mutation, in absence of mutations in PO, PMP22, and Cx32 (coding region and promoter) genes, in a patient diagnosed as having a severe CMT1. This mutation predicts in the full-length protein a substitution of the aspartic acid to valine in position 355 (D355V), previously named D305V (Bellone et al., 1999; CMT Mutation Database: http://molgen-www. uia.ac.be/CMTMutations/).
Here we show that this mutation marginally affects the DNA-binding affinity for the EGR2 consensus sequence and leads instead to a dramatic reduction of the affinity for the sequence 5Ј-GGGTGGGCG-3Ј located 93 bp upstream of the transcription start site in the human Cx32 promoter (GenBank Accession No. GI974140). These data may suggest a direct role of
